At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

Use of the antihypertensive medications improved survival whether or not patients fully recovered from acute kidney injury. Initiating or resuming renin-angiotensin-aldosterone system (RAAS) blockade ...

Credit: Getty Images. The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of ...

Investigators found no definitive benefit of dual RAAS blockade in preventing kidney failure in patients with ADPKD. For patients with autosomal dominant polycystic kidney disease (ADPKD), intensive ...

Unique Characteristics of Hypertension in Blacks That Influence BP Responses to Drugs That Block the Renin-Angiotensin Activating System (RAAS) Blockade of the RAAS in Blacks for Cardiovascular and ...

Blockade of the renin-angiotensin-aldosterone system (RAAS) is a standard treatment for patients with chronic kidney disease (CKD). Intensive strategies with single-agent or dual-agent RAAS blockade ...

It's long been known that use of a renin-angiotensin-aldosterone system (RAAS) antagonist slows the progression of kidney disease and specifically slows progression of advanced kidney disease, ...

"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

Glomerulonephritis (GN) is a diverse group of diseases, not a single entity, and remains a primary driver of end-stage renal disease (ESRD). The renal biopsy remains the essential tool for definitive ...

Please provide your email address to receive an email when new articles are posted on . RAS blockers had similar mortality benefit by race in patients with HFrEF. RAS blockers improved HF ...